Raymond James Financial Inc. Has $91.84 Million Stock Holdings in Insulet Corporation $PODD

Key Points

• Raymond James Financial Inc. increased its stake in Insulet Corporation by 31.5%, acquiring an additional 83,743 shares during the first quarter, bringing its total shares owned to 349,700.
• Insulet Corporation reported earnings of $1.17 per share for the quarter, surpassing analysts' expectations of $0.92, with a year-over-year revenue increase of 32.9% to $649.10 million.
• Several analysts have rated Insulet with a consensus "Moderate Buy", with target prices ranging from $330.00 to $350.00, indicating positive investor sentiment towards the stock.

Raymond James Financial Inc. boosted its holdings in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 31.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 349,700 shares of the medical instruments supplier's stock after buying an additional 83,743 shares during the quarter. Raymond James Financial Inc. owned about 0.50% of Insulet worth $91,835,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of PODD. OLD National Bancorp IN grew its position in Insulet by 6.7% during the first quarter. OLD National Bancorp IN now owns 880 shares of the medical instruments supplier's stock worth $231,000 after buying an additional 55 shares in the last quarter. Cooper Financial Group grew its position in Insulet by 5.7% during the first quarter. Cooper Financial Group now owns 1,079 shares of the medical instruments supplier's stock worth $283,000 after buying an additional 58 shares in the last quarter. Syon Capital LLC grew its position in Insulet by 5.6% during the fourth quarter. Syon Capital LLC now owns 1,114 shares of the medical instruments supplier's stock worth $291,000 after buying an additional 59 shares in the last quarter. MassMutual Private Wealth & Trust FSB grew its position in Insulet by 23.1% during the first quarter. MassMutual Private Wealth & Trust FSB now owns 314 shares of the medical instruments supplier's stock worth $82,000 after buying an additional 59 shares in the last quarter. Finally, HighTower Advisors LLC grew its position in Insulet by 2.1% during the first quarter. HighTower Advisors LLC now owns 2,882 shares of the medical instruments supplier's stock worth $757,000 after buying an additional 60 shares in the last quarter.

Insulet Trading Up 0.9%

PODD stock traded up $2.92 during trading on Friday, hitting $330.77. The company had a trading volume of 499,504 shares, compared to its average volume of 705,185. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. The firm has a 50-day moving average price of $300.94 and a 200-day moving average price of $285.90. Insulet Corporation has a 12 month low of $180.31 and a 12 month high of $334.18. The stock has a market cap of $23.28 billion, a price-to-earnings ratio of 100.54, a PEG ratio of 2.75 and a beta of 1.35.

Insulet (NASDAQ:PODD - Get Free Report) last released its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, topping analysts' consensus estimates of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The firm had revenue of $649.10 million during the quarter, compared to analyst estimates of $612.31 million. During the same quarter in the previous year, the business earned $0.55 EPS. The business's quarterly revenue was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, analysts predict that Insulet Corporation will post 3.92 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Wall Street Zen raised Insulet from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Raymond James Financial restated an "outperform" rating and set a $360.00 price target (up previously from $328.00) on shares of Insulet in a research note on Tuesday, May 27th. Morgan Stanley reiterated an "overweight" rating on shares of Insulet in a research note on Thursday, August 7th. Sanford C. Bernstein reiterated an "outperform" rating on shares of Insulet in a research note on Friday, May 16th. Finally, The Goldman Sachs Group began coverage on shares of Insulet in a research note on Friday, May 30th. They issued a "buy" rating and a $380.00 target price for the company. Sixteen analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $332.71.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.